These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 24756802)

  • 41. [Proteasome inhibitors].
    Saeki Y; Fukunaga K; Tanaka K
    Nihon Rinsho; 2010 Oct; 68(10):1818-22. PubMed ID: 20954323
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of bortezomib on bone health in myeloma: a review of current evidence.
    Zangari M; Terpos E; Zhan F; Tricot G
    Cancer Treat Rev; 2012 Dec; 38(8):968-80. PubMed ID: 22226939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS
    Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Development and clinical application of novel proteasome inhibitors].
    Iida S
    Rinsho Ketsueki; 2012 Apr; 53(4):417-25. PubMed ID: 22687975
    [No Abstract]   [Full Text] [Related]  

  • 45. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
    Cavo M
    Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
    Huber EM; Groll M
    Angew Chem Int Ed Engl; 2012 Aug; 51(35):8708-20. PubMed ID: 22711561
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of bortezomib in the treatment of lymphoma.
    Barr P; Fisher R; Friedberg J
    Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The ubiquitin-proteasome-system.
    Sommer T; Wolf DH
    Biochim Biophys Acta; 2014 Jan; 1843(1):1. PubMed ID: 24055503
    [No Abstract]   [Full Text] [Related]  

  • 49. [Proteasome inhibitors in cancer therapy].
    Romaniuk W; Ołdziej AE; Zińczuk J; Kłoczko J
    Postepy Hig Med Dosw (Online); 2015 Dec; 69():1443-50. PubMed ID: 27259216
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Proteasome inhibitor bortezomib as an anticancer drug].
    Yasui H; Hideshima T
    Tanpakushitsu Kakusan Koso; 2006 Aug; 51(10 Suppl):1251-6. PubMed ID: 16922383
    [No Abstract]   [Full Text] [Related]  

  • 51. Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
    Piro E; Kropp M; Cantaffa R; Lamberti AG; Carillio G; Molica S
    Ann Hematol; 2012 Nov; 91(11):1827-8. PubMed ID: 22584850
    [No Abstract]   [Full Text] [Related]  

  • 52. From bortezomib to other inhibitors of the proteasome and beyond.
    Buac D; Shen M; Schmitt S; Kona FR; Deshmukh R; Zhang Z; Neslund-Dudas C; Mitra B; Dou QP
    Curr Pharm Des; 2013; 19(22):4025-38. PubMed ID: 23181572
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteasome inhibitor drugs on the rise.
    Joazeiro CA; Anderson KC; Hunter T
    Cancer Res; 2006 Aug; 66(16):7840-2. PubMed ID: 16861477
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Targeting apoptosis in solid tumors: the role of bortezomib from preclinical to clinical evidence.
    Russo A; Fratto ME; Bazan V; Schiró V; Agnese V; Cicero G; Vincenzi B; Tonini G; Santini D
    Expert Opin Ther Targets; 2007 Dec; 11(12):1571-86. PubMed ID: 18020979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical and marketed proteasome inhibitors for cancer treatment.
    Zhang J; Wu P; Hu Y
    Curr Med Chem; 2013; 20(20):2537-51. PubMed ID: 23531219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting proteasomal protein degradation in cancer-letter.
    Wu WK
    Clin Cancer Res; 2012 Feb; 18(3):912. PubMed ID: 22247496
    [No Abstract]   [Full Text] [Related]  

  • 57. Non-covalent proteasome inhibitors.
    Kaffy J; Bernadat G; Ongeri S
    Curr Pharm Des; 2013; 19(22):4115-30. PubMed ID: 23181573
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Boron chemicals in diagnosis and therapeutics.
    Das BC; Thapa P; Karki R; Schinke C; Das S; Kambhampati S; Banerjee SK; Van Veldhuizen P; Verma A; Weiss LM; Evans T
    Future Med Chem; 2013 Apr; 5(6):653-76. PubMed ID: 23617429
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New agents for the treatment of lymphoma.
    Stathis A; Ghielmini M
    Ann Oncol; 2012 Sep; 23 Suppl 10():x92-8. PubMed ID: 22988000
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Study on natural products for drug development].
    Tsukamoto S
    Yakugaku Zasshi; 2010 Oct; 130(10):1273-81. PubMed ID: 20930478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.